Parasol Investment Management LLC reduced its position in Pfizer, Inc. (NYSE:PFE) by 56.4% during the first quarter, Holdings Channel reports. The fund owned 3,875 shares of the biopharmaceutical company’s stock after selling 5,010 shares during the period. Parasol Investment Management LLC’s holdings in Pfizer were worth $133,000 at the end of the most recent quarter.
A number of other institutional investors have also recently modified their holdings of PFE. Norges Bank purchased a new position in shares of Pfizer during the fourth quarter worth about $1,896,890,000. Macquarie Group Ltd. boosted its position in shares of Pfizer by 8.2% in the fourth quarter. Macquarie Group Ltd. now owns 24,455,341 shares of the biopharmaceutical company’s stock worth $794,310,000 after buying an additional 1,845,343 shares during the last quarter. FMR LLC boosted its position in shares of Pfizer by 22.0% in the fourth quarter. FMR LLC now owns 21,970,338 shares of the biopharmaceutical company’s stock worth $713,596,000 after buying an additional 3,958,324 shares during the last quarter. Teachers Advisors LLC boosted its position in shares of Pfizer by 2.3% in the fourth quarter. Teachers Advisors LLC now owns 13,664,429 shares of the biopharmaceutical company’s stock worth $443,821,000 after buying an additional 310,730 shares during the last quarter. Finally, Asset Management One Co. Ltd. boosted its position in shares of Pfizer by 618.4% in the fourth quarter. Asset Management One Co. Ltd. now owns 11,094,592 shares of the biopharmaceutical company’s stock worth $360,362,000 after buying an additional 9,550,335 shares during the last quarter. 69.95% of the stock is owned by institutional investors and hedge funds.
Shares of Pfizer, Inc. (NYSE PFE) opened at 33.25 on Tuesday. The company’s 50 day moving average price is $32.80 and its 200 day moving average price is $33.17. Pfizer, Inc. has a 12 month low of $29.83 and a 12 month high of $37.39. The company has a market cap of $198.43 billion, a price-to-earnings ratio of 27.99 and a beta of 1.01.
Pfizer (NYSE:PFE) last announced its quarterly earnings results on Tuesday, May 2nd. The biopharmaceutical company reported $0.69 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $0.67 by $0.02. Pfizer had a return on equity of 23.68% and a net margin of 13.76%. The company had revenue of $12.78 billion for the quarter, compared to the consensus estimate of $13.09 billion. During the same quarter in the previous year, the business earned $0.67 EPS. Pfizer’s revenue was down 1.7% compared to the same quarter last year. On average, equities analysts expect that Pfizer, Inc. will post $2.55 EPS for the current fiscal year.
The firm also recently declared a quarterly dividend, which will be paid on Friday, September 1st. Investors of record on Friday, August 4th will be issued a dividend of $0.32 per share. The ex-dividend date is Wednesday, August 2nd. This represents a $1.28 dividend on an annualized basis and a yield of 3.85%. Pfizer’s dividend payout ratio is presently 108.48%.
COPYRIGHT VIOLATION NOTICE: “Pfizer, Inc. (NYSE:PFE) Stake Reduced by Parasol Investment Management LLC” was first reported by Community Financial News and is the sole property of of Community Financial News. If you are viewing this news story on another domain, it was illegally copied and reposted in violation of U.S. and international copyright law. The legal version of this news story can be accessed at https://www.com-unik.info/2017/07/18/pfizer-inc-nysepfe-stake-reduced-by-parasol-investment-management-llc.html.
PFE has been the subject of a number of recent research reports. Sanford C. Bernstein reaffirmed a “buy” rating and issued a $35.00 target price on shares of Pfizer in a report on Monday, April 24th. Societe Generale reaffirmed a “neutral” rating and issued a $36.00 target price on shares of Pfizer in a report on Thursday, March 23rd. Jefferies Group LLC reaffirmed a “hold” rating and issued a $35.00 target price (up previously from $34.00) on shares of Pfizer in a report on Friday. BidaskClub cut Pfizer from a “sell” rating to a “strong sell” rating in a report on Thursday, July 13th. Finally, Zacks Investment Research raised Pfizer from a “sell” rating to a “hold” rating in a report on Friday. Two equities research analysts have rated the stock with a sell rating, eleven have issued a hold rating and eleven have given a buy rating to the company’s stock. Pfizer has an average rating of “Hold” and an average target price of $37.78.
Pfizer Inc (Pfizer) is a research-based global biopharmaceutical company. The Company is engaged in the discovery, development and manufacture of healthcare products. Its global portfolio includes medicines and vaccines, as well as consumer healthcare products. The Company manages its commercial operations through two business segments: Pfizer Innovative Health (IH) and Pfizer Essential Health (EH).
Want to see what other hedge funds are holding PFE? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Pfizer, Inc. (NYSE:PFE).
What are top analysts saying about Pfizer Inc.? - Enter your email address in the form below to receive our free daily email newsletter that contains the latest headlines and analysts' recommendations for for Pfizer Inc. and related companies.